Intra-Cellular Therapies Sees 2024 CAPLYTA Net Product Sales $650M-$680M
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies has projected its 2024 net product sales for CAPLYTA to be between $650 million and $680 million.
August 07, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies has projected its 2024 net product sales for CAPLYTA to be between $650 million and $680 million.
The projected sales figures for CAPLYTA indicate strong expected performance, which is likely to positively impact ITCI's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100